The role of parotid gland biopsy in early detection of lymphoma in primary Sjogren's syndrome


Aim. To investigate the incidence of MALT-lymphoma in Sjogren's disease by means of biopsy of the enlarged parotid glands.
Material and methods. The incisional parotid biopsy was performed in 57 primary Sjogren's syndrome (pSS) patients with existing parotid enlargement. The median age was 54 years (range 19-75 years). The median pSS duration was 7 years (range 1-30 years). The palpable parotid enlargement was defined as grade 1 and massive (visional) enlargement of the parotid glands was defined as grade 2. Histologic and immunohistochemical examinations for diagnosis of lymphoma were made. High resolution electrophoresis and immunofixation were performed for detection of monoclonal immunoglobulins in the serum and their free light chains in the urine.
Results. Biopsy of he enlarged parotid glands identified MALT-lymphoma in 37 of 57 (64.9%) pSS patients. Of 37 pSS patients with parotid enlargement of grade 2, diagnosis of MALT-lymphoma was made in 89.2%. Of 20 pSS patients who had parotid enlargement of grade 1, MALT-lymphoma was diagnosed in 20%. In patients with grade 1 enlarged parotid glands MALT-lymphoma was identified only in cases with the presence of monoclonal immunoglobulins in the serum and their free light chains in the urine (3 of 4 patients) or in case of disseminated disease (lymphoma involved regional lymph nodes and soft tissues of the face) - 1 of 4 patients. In patients with grade 2 enlargement of parotid glands MALT-lymphoma located most frequently in affected parotid glands (69.6%).
Conclusion. The incisional biopsy of enlarged parotid glands is necessary for detection of MALT lymphoma in pSS patients.


  1. Родионова Е. Б., Тупицин Н. Н., Васильев В. И. и др. Изучение уровня экспрессии HLA-DR молекул на поверхности эпителиальных клеток малых слюнных желез при болезни Шегрена. Иммунология 2005; 6: 357-359.
  2. Dimitriou I., Kapsogeorgou E., Moutsopoulos H. et al. CD40 on salivary gland epithelial cell: high constitutive expression by cultured cell from Sjogren's syndrome patients indicating their intrinsic activation. Clin. Exp. Immunol. 2002; 127: 386-392.
  3. Fox R., Koh K., Saito I. Lymphoproliferative disorders in Sjцgren's syndrome. In: Homma M., Sugai S., Tojo T. et al. (eds). Sjцgren's syndrome. State of the art Amsterdam: Kugler; 1994. 199-203.
  4. Xanthou G., Polihronis M., Tzioufas A. et al. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjцgren's syndrome patients. Possible participation in lymphoid structure formation. Arthr. and Rheum. 2001; 44: 408-418.
  5. Jonsson R., Gordon Т., Konttinen Y. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjцgren's syndrome. Curr. Rheum. Rep. 2003; 5: 311-316.
  6. Palmer R., Eveson J., Gusterson B. 'Epimyoepimelial' islands in lymphoepithelial lesions: an immunohistochemical study. Virchows Arch. A. Pathol. Anat. Histopathol. 1986; 408: 603-609.
  7. Falzon M., Isaacson P. The natural history of benign lymphoepithelial lesion of the salivary gland in which there is a monoclonal population of В cells. Am. J. Surg. Pathol. 1991; 15: 59-65.
  8. Isaacson P., Wright D. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. (Philad.) 1984; 53: 2515-2524.
  9. Васильев В. И. Синдром Шегрена. В кн.: Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: ГЭОТАР-Медицина; 2008. 484-502.
  10. Ioannidis J., Vassiliou V., Moutsopoulos H. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjцgren's syndrome. Arthr. and Rheum. 2002; 46: 741-747.
  11. Kruize A., Hene R., van der Heide A. et al. Long-term followup of patients with Sjцgren's syndrome. Arthr. and Rheum. 1996; 39: 297-303.
  12. Scopouli F., Dafni U., loannidis J. et al. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin. Arthr. Rheum. 2000; 29: 296-304.
  13. Kassan S., Thomas Т., Moutsopoulos H. et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med. 1978; 89: 888-892.
  14. Sutcliffe N., Inanс M., Speight P. et al. Predictor of lymphoma development in primary Sjцgren's syndrome. Semin. Arthr. Rheum. 1998; 28: 80-87.
  15. Васильев В. И., Пробатова Н. А., Тупицин Н. Н. и др. MALT-лимфомы при болезни Шегрена. Тер. арх. 2006; 1: 45-52.
  16. Royer В., Cazals-Hatem D., Sibilia J. et al. Lymphomas in patients with Sjцgren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997; 90: 766-775.
  17. Voulgarelis M., Dafni U., Isenberg D. et al. Malignant lymphoma in primary Sjogren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjцgren's syndrome. Arthr. and Rheum. 1999; 42: 1765-1772.
  18. Городецкий В. Р., Васильев В. И., Пробатова Н. А. и др. Лимфомы у больных с синдромом Шегрена. Рос. мед. журнал 2003; 1: 10-13.
  19. Fox P., Hong C., Bran A. et al. Diagnosis and management of autoimmune salivary gland disorders. In: Myers E., Ferris R. (eds.) Salivary gland disorders. Berlin: Springer; 2007. 201-221.
  20. Васильев В. И., Пробатова Н. А., Тупицын Н. Н. и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология 2007; 3: 16-26.
  21. Васильев В. И., Симонова М. В., Сафонова Т. Н. Критерии диагноза болезни и синдрома Шегрена. В кн.: Насонова В. А., Бунчук Н. В. (ред.). Избранные лекции по клинической ревматологии. М: Медицина; 2001. 112-132.
  22. Marx R., Hartman К., Rethman К. A prospective study comparing incisional labial to incisional parotid biopsies in the detection and confirmation of sarcoidosis, Sjцgren's disease, sialosis and lymphoma. J. Rheumatol. 1988; 15: 621-629.
  23. Jordan R., Odell E., Speight P. B-cell monoclonality in salivary lymphoepithelial lesions. Oral Oncol. Eur. J. Cancer. 1996; 32B: 38-44.
  24. Hyjek E., Smith W., Isaacson P. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum. Pathol. 1988; 19: 766-776.
  25. Harris N. Lymphoid proliferations of the salivary glands. Am. J. Clin. Pathol. 1999; 111 (suppl. 1): 94-103.
  26. Cavalli F., Isaacson P., Gascoyne R. et al. MAET lymphomas. Hematology 2001; 1: 241-258.
  27. Theander E., Henriksson G., Ljungberg O. et al. Lymphoma and other malignancies in primary Sjцgren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis. 2006; 65: 796-803.
  28. Lazarus M., Robinson D., Mak V. et al. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology 2006; 45: 1012-1015.
  29. Hernandez J., Olive A., Ribera J. et al. Probability of the development of non-Hodgkin's lymphoma in primary Sjцgren's syndrome. Scand. J. Rheumatol. 1996; 25: 96-97.
  30. Логвиненко О. А. Моноклональные иммуноглобулины при болезни Шегрена: Автореф. дис. ... канд. мед. наук. М., 2006.
  31. Walters М., Stevenson F., Herbert A. et al. Urinary monoclonal free light chains in primary Sjogren's syndrome: an aid to the diagnosis of malignant lymphoma. Ann. Rheum. Dis. 1986; 45: 210-219.
  32. Martin Т., Weber J., Levallois H. et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor В cells. Arthr. and Rheum. 2000; 43: 908-916.
  33. Pijpe J., Kalk W., van der Wal J. et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjцgren's syndrome. Rheumatology 2007; 46: 335-341.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies